Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 03, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,149Price:$6.20
-
Apr 03, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,047Price:$6.20
-
Apr 03, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-103,870Price:$6.20
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,050Price:$6.65
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-22,084Price:$6.65
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-76,346Price:$6.65
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,451Price:$6.99
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-39,411Price:$6.99
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-136,255Price:$6.99
-
Mar 19, 2024 (filed on Mar 19, 2024)Insider Name:Kuriakose EmilOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
Filings by filing date
-
Apr 03, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,149Price:$6.20
-
Apr 03, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-30,047Price:$6.20
-
Apr 03, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-103,870Price:$6.20
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,050Price:$6.65
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-22,084Price:$6.65
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-76,346Price:$6.65
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,451Price:$6.99
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-39,411Price:$6.99
-
Apr 01, 2024 (filed on Apr 03, 2024)Insider Name:Vivo Opportunity, LLCOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-136,255Price:$6.99
-
Mar 19, 2024 (filed on Mar 19, 2024)Insider Name:Kuriakose EmilOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1065 East Hillsdale Blvd. Suite 100, Suite 100 FOSTER CITY CA 94404 |
Tel: | N/A |
Website: | https://ternspharma.com |
IR: | See website |
Key People | ||
Erin Quirk President, Head of Research & Development | Amy L. Burroughs Chief Executive Officer, Director | Mark J. Vignola Chief Financial Officer, Treasurer |
Bryan Yoon Chief Operating Officer, General Counsel, Secretary | Sun Jung Chief Business Officer | Emil T. Kuriakose Chief Medical Officer - Oncology | Kerry Russell Chief Medical Officer - Metabolic |
Business Overview |
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. |
Financial Overview |
For the fiscal year ended 31 December 2023, Terns Pharmaceuticals Inc revenues was not reported. Net loss increased 49% to $90.2M. Higher net loss reflects Research and development - Balancing v increase of 57% to $57.6M (expense), Stock-based Compensation in SGA increase from $7.7M to $19.7M (expense), General and administrative - Balancing increase of 32% to $19.4M (expense). |
Employees: | 66 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $43.66M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$102.27M as of Dec 31, 2023 |
Net annual income (TTM): | -$90.21M as of Dec 31, 2023 |
Free cash flow (TTM): | -$67.44M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 64,651,693 as of Mar 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |